OTC Markets OTCPK - Delayed Quote USD

Finch Therapeutics Group, Inc. (FNCH)

1.3300 -0.0200 (-1.48%)
At close: June 7 at 2:10 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
--
107.0000
861.0000
18,532.0000
7,719.0000
--
Cost of Revenue
--
--
--
--
--
314.0000
Gross Profit
--
--
--
--
7,719.0000
9,840.0000
Operating Expense
22,660.0000
34,109.0000
89,055.0000
78,517.0000
47,155.0000
--
Operating Income
-22,660.0000
-34,002.0000
-88,194.0000
-59,985.0000
-39,436.0000
--
Net Non Operating Interest Income Expense
1,425.0000
1,570.0000
252.0000
22.0000
106.0000
--
Other Income Expense
4,952.0000
-45,783.0000
-26,704.0000
1,803.0000
-11.0000
--
Pretax Income
-16,283.0000
-78,215.0000
-114,646.0000
-58,160.0000
-39,341.0000
--
Tax Provision
--
-3,461.0000
--
--
--
--
Net Income Common Stockholders
-16,283.0000
-74,754.0000
-114,646.0000
-58,160.0000
-39,341.0000
--
Diluted NI Available to Com Stockholders
-16,283.0000
-74,754.0000
-114,646.0000
-58,160.0000
-39,341.0000
--
Basic EPS
-9.81
-46.59
-72.12
-44.40
-25.72
--
Diluted EPS
-9.81
-46.59
-72.12
-44.40
-25.72
--
Basic Average Shares
1,605.2770
1,604.5490
1,589.5840
1,306.7360
1,529.8460
--
Diluted Average Shares
1,605.2770
1,604.5490
1,589.5840
1,306.7360
1,529.8460
--
Total Operating Income as Reported
-23,276.0000
-83,861.0000
-115,593.0000
-59,985.0000
-39,436.0000
--
Total Expenses
22,660.0000
34,109.0000
89,055.0000
78,517.0000
47,155.0000
--
Net Income from Continuing & Discontinued Operation
-16,283.0000
-74,754.0000
-114,646.0000
-58,160.0000
-39,341.0000
--
Normalized Income
-17,193.0000
-27,130.7184
-87,240.0000
-60,015.0000
-39,328.0000
--
Interest Income
--
1,570.0000
252.0000
22.0000
106.0000
--
Net Interest Income
1,425.0000
1,570.0000
252.0000
22.0000
106.0000
--
EBIT
-22,660.0000
-34,002.0000
-88,194.0000
-59,985.0000
-39,436.0000
--
EBITDA
-22,464.0000
-32,482.0000
-82,687.0000
-57,684.0000
-38,646.0000
--
Reconciled Cost of Revenue
--
--
--
--
--
314.0000
Reconciled Depreciation
196.0000
1,520.0000
5,507.0000
2,301.0000
790.0000
--
Net Income from Continuing Operation Net Minority Interest
-16,283.0000
-74,754.0000
-114,646.0000
-58,160.0000
-39,341.0000
--
Total Unusual Items Excluding Goodwill
910.0000
-49,836.0000
-27,406.0000
1,855.0000
-13.0000
--
Total Unusual Items
910.0000
-49,836.0000
-27,406.0000
1,855.0000
-13.0000
--
Normalized EBITDA
-23,374.0000
17,354.0000
-55,281.0000
-59,539.0000
-38,633.0000
--
Tax Rate for Calcs
--
0.0000
--
--
--
--
Tax Effect of Unusual Items
--
-2,212.7184
--
--
--
--
12/31/2019 - 3/19/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NEXI NexImmune, Inc.
3.0000
-5.36%
 
CRVO CervoMed Inc.
19.19
-0.36%
 
QNCX Quince Therapeutics, Inc.
0.7900
-5.99%
 
HOWL Werewolf Therapeutics, Inc.
3.4900
-0.29%
 
BRNS Barinthus Biotherapeutics plc
1.9900
+2.58%
 
CNTB Connect Biopharma Holdings Limited
1.9600
+16.67%
 
PALI Palisade Bio, Inc.
4.5700
-2.56%
 
SLRX Salarius Pharmaceuticals, Inc.
0.4110
-6.59%
 
KZIA Kazia Therapeutics Limited
0.2495
-1.73%
 
KOD Kodiak Sciences Inc.
2.8900
-3.99%